|

Dinutuximab Clinical Trials

3 actively recruiting trials across 2 locations

▼ -1 trial since August 2026

Also known as: Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, Qarziba +2 more

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • New Approaches to Neuroblastoma Therapy Consortium1
  • National Cancer Institute (NCI)1
  • Children's Oncology Group1

Indications

  • Neuroblastoma3
  • Cancer3
  • Ganglioneuroblastoma, Nodular2
  • Ganglioneuroblastoma1

Birmingham, Alabama2 trials

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3

Los Angeles, California1 trial

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Children's Hospital Los Angeles

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.